Recorded Presentation from the NCCN 2017 Nursing Program Webinar Series - Clinical Updates and Issues: Bladder Cancer
The 2017 NCCN Nursing Program: Advancing Oncology Nursing Live Webinar Series will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting.
This activity is designed to meet the educational needs of oncology nurses who manage patients with cancer.
Following this activity, participants should be able to:
- Evaluate the clinical utility of immunotherapies in patients with bladder cancer
- Summarize the adverse events associated the use of immunotherapies in bladder cancer
- Implement strategies for the prevention and management of treatment-related toxicities
Erika Barrett Meneely, NP
Massachusetts General Hospital Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below discloses no relevant financial relationships:
Erika Barrett Meneely, NP
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until 2/7/17); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until 2/3/17); Gary J. Weyhmuller, MBA, SPHR
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Mary Anne Bergman; Mary Dwyer, MS; Ellen Erkess Uskuraitis; Deborah Freedman-Cass, PhD; Lisa Gurski, PhD; Miranda Hughes, PhD; Rashmi Kumar, PhD; Jillian Scavone, PhD; Hema Sundar, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.70 contact hours.
- 0.70 ANCC contact hours
- 0.70 Participation